Published in BMB Rep on August 01, 2015
Viral Therapy in Treating Young Patients With Relapsed or Refractory Solid Tumors | NCT01240538
Viral Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT01533194
Safety and Efficacy Study of REOLYSIN® in the Treatment of Recurrent Malignant Gliomas | NCT00528684
Viral Therapy in Treating Patients With Metastatic Melanoma | NCT00651157
A Study of Reolysin For Patients With Advanced/Metastatic Breast Cancer | NCT01656538
Oncogenes: The Passport for Viral Oncolysis Through PKR Inhibition. Biomark Cancer (2016) 0.75
Cancer drug resistance: an evolving paradigm. Nat Rev Cancer (2013) 6.77
Reoviruses. A new group of respiratory and enteric viruses formerly classified as ECHO type 10 is described. Science (1959) 4.78
Characteristics of poliomyelitis and other enteric viruses recovered in tissue culture from healthy American children. Proc Soc Exp Biol Med (1954) 4.30
Reovirus therapy of tumors with activated Ras pathway. Science (1998) 4.15
Genome RNAs and polypeptides of reovirus serotypes 1, 2, and 3. J Virol (1977) 3.87
Enteropathogenic viruses and bacteria; role in summer diarrheal diseases of infancy and early childhood. J Am Med Assoc (1958) 3.17
The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J (1998) 2.62
Intestinal viral flora of healthy children demonstrable by monkey kidney tissue culture. Am J Public Health Nations Health (1956) 2.46
A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin Cancer Res (2008) 2.18
Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor. Proc Natl Acad Sci U S A (2006) 1.96
Studies on the pathogenesis of a hitherto undescribed virus (hepato-encephalomyelitis) producing unusual symptoms in suckling mice. Aust J Exp Biol Med Sci (1953) 1.95
A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas. Mol Ther (2008) 1.81
Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies. Clin Cancer Res (2012) 1.67
REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer. Clin Cancer Res (2010) 1.53
Synergistic interaction between oncolytic viruses augments tumor killing. Mol Ther (2010) 1.51
Reovirus infections in human volunteers. Am J Hyg (1963) 1.43
A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer. Clin Cancer Res (2010) 1.42
The preferential cytotoxicity of reovirus for certain transformed cell lines. Arch Virol (1977) 1.39
c-Myc: linking transformation and genomic instability. Curr Mol Med (2008) 1.35
Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers. Clin Cancer Res (2010) 1.35
Differential sensitivity of normal and transformed human cells to reovirus infection. J Virol (1978) 1.32
Phase II trial of intravenous administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma. Mol Ther (2012) 1.20
The ever expanding role for c-Myc in promoting genomic instability. Cell Cycle (2007) 1.15
REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors. Invest New Drugs (2012) 1.02
Chromosome instability and deregulated proliferation: an unavoidable duo. Cell Mol Life Sci (2012) 0.99
The viral tropism of two distinct oncolytic viruses, reovirus and myxoma virus, is modulated by cellular tumor suppressor gene status. Oncogene (2010) 0.98
c-Myc, Genomic Instability and Disease. Genome Dyn (2006) 0.96
Phase 1 clinical trial of intratumoral reovirus infusion for the treatment of recurrent malignant gliomas in adults. Mol Ther (2014) 0.96
Reovirus type 3 infection in patients with primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol (1987) 0.95
Naturally oncolytic viruses. Curr Opin Mol Ther (2006) 0.94
Characteristics of a newborn runt disease induced by neonatal infection with an oncolytic strain of reovirus type 3 (REO3MH). I. Pathological investigations in rats and mice. Br J Exp Pathol (1967) 0.92
The prevalence of antibodies to reovirus type 3 in adults with idiopathic cholestatic liver disease. J Med Virol (1985) 0.90
The oncolytic effect in vivo of reovirus on tumour cells that have survived reovirus cell killing in vitro. Br J Cancer (2006) 0.90
Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic. Curr Opin Mol Ther (2006) 0.90
Isolation of a non-pathogenic tumour-destroying virus from mouse ascites. Nature (1960) 0.89
Acquired resistance to reoviral oncolysis in Ras-transformed fibrosarcoma cells. Oncogene (2007) 0.89
An oncolytic virus recovered from Swiss mice during passage of an ascites tumour. Nature (1960) 0.88
Attenuated reovirus displays oncolysis with reduced host toxicity. Br J Cancer (2010) 0.87
Reovirus and tumor oncolysis. J Microbiol (2007) 0.86
Morbidity in immunosuppressed (SCID/NOD) mice treated with reovirus (dearing 3) as an anti-cancer biotherapeutic. Cancer Biol Ther (2004) 0.85
The combined effects of oncolytic reovirus plus Newcastle disease virus and reovirus plus parvovirus on U87 and U373 cells in vitro and in vivo. J Neurooncol (2011) 0.83
All reovirus subtypes show oncolytic potential in primary cells of human high-grade glioma. Oncol Rep (2011) 0.81
Replicating poxviruses for human cancer therapy. J Microbiol (2015) 0.81